CAR NK biotech Catamaran Bio to wind down, will seek partners for cell therapies
Off-the-shelf cell therapy biotech Catamaran Bio made a “recent decision to commence wind-down,” CEO Alvin Shih told Endpoints News in an email on Monday.
The Boston biotech will cease day-to-day operations and seek strategic partners for its CAR NK cell therapy candidates and technology, Shih wrote in a LinkedIn post on Monday. Catamaran had 19 employees as of Monday morning, he told Endpoints, and a “handful” will stay on for a transition period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.